
Conference Coverage
Latest Content

The New Realities of DSCSA Compliance

It’s Official: CMS Unveils Big Price Cuts for 15 High-Cost Medicare Drugs in Latest IRA Negotiation Round

What Sets True DSCSA Readiness Apart?

Pharma Pulse: Medicare Price Negotiations Heat Up, as FDA Approves SMA Gene Therapy

Medicare Set to Unveil Prices for 15 High-Cost Drugs

Shorts










Podcasts
All News

In the third part of his Pharma Commerce video interview, Brad Stewart, BDO’s national life sciences co-leader, explains that while the FDA has not defined the specific level of manufacturing commitment needed to improve US supply chain resilience, applicants for the voucher should focus on linking unique or rare disease therapies—particularly in areas like oncology—with domestic onshoring efforts to move their applications to the top of the pile for selection.

Pharma Pulse: RSV Protection Wanes, AstraZeneca Invests Big, and Novo Nordisk Faces Pipeline Setback
A new Pharma Pulse briefing unpacks declining RSV vaccine durability in older adults, AstraZeneca’s $2 billion expansion of its US biologics manufacturing footprint, and the stock-shaking Phase III struggle affecting Novo Nordisk’s Alzheimer’s ambitions.

Moderna secures a $1.5 billion loan to enhance financial flexibility while targeting a 10% revenue growth by 2026, focusing on innovative mRNA therapies.

The pharmaceutical giant will be nearly doubling biologics production in Frederick and build a new clinical supply facility in Gaithersburg, projects that will create thousands of jobs, enhance US supply chain resilience, and advance its growing rare disease portfolio.

In the final part of her Pharma Commerce video interview, Christy Christian, senior industry principal with Kinaxis, highlights a future where AI, cleaner data, and exception-based decision-making accelerate response times and strengthen end-to-end supply chain visibility.

Abbott's deal shakes up cancer diagnostics, new research confirms pandemic fatigue's impact on public compliance, and more in today’s Pharma Pulse.

When intelligence flows across clinical, access, and engagement channels, commercialization shifts from reactive to predictive, giving teams the real-time edge to win in a fast-moving market.

In the second part of his Pharma Commerce video interview, Brad Stewart, BDO’s national life sciences co leader, reveals how National Priority Vouchers—and geopolitical pressure—are reshaping decisions around supply chain investment.

While studies reveal the complex, varying, and long-lasting burden of Long COVID symptoms, biopharma giants Novartis and Moderna commit significant capital to new facilities, reinforcing US drug supply resilience in today’s Pharma Pulse.

As part of its multi-billion-dollar investment, the company will be creating a unified, end-to-end manufacturing campus spanning biologics, gene therapy, solid dosage, and packaging operations.

In the first part of his Pharma Commerce video interview, Brad Stewart, BDO’s national life sciences co leader, explains why large-volume, high-need drugs—especially those heavily sourced overseas—may be the strongest candidates, and how the pandemic’s supply chain lessons are influencing the program’s future direction.

In today’s Pharma Pulse, we dissect the resource drain of new pilot programs, the growing concerns over global supply chain dependency, and the simple tech intervention improving glycemic control.

In final part of his Pharma Commerce video interview, Faisal Khan, a GRC solutions expert with Vanta, points out how leadership buy-in, role-based training, and “cyber moments” can reinforce continuous awareness and shared responsibility across the organization.

A US-China Economic and Security Review Commission report highlights China’s tightening grip on APIs, biomanufacturing, and R&D services, raising alarms about supply chain vulnerabilities, data transparency gaps, and the urgent need for US policy action.

In today’s Pharma Pulse, learn how digital pharmacy safety gaps, Novo Nordisk’s introductory programs for Wegovy and Ozempic, and Scott Gottlieb’s new role at UnitedHealth are shaping patient access and industry strategy.













